OncoOne is actively seeking investors and strategic partners to support the filing of investigational new drug applications (INDs/IMPDs) for two of its lead antibody drug candidates, ON104 and ON203, and to evaluate these therapeutics in the clinic as early as 2024. Both assets address therapeutic indications with high unmet medical need and large market potential. OncoOne, a Vienna-based biotech company was founded in 2018 and is dedicated to generating innovative therapeutics utilizing its profound protein engineering, antibody research, and drug development expertise. The company is developing novel therapeutics for patients with solid tumors and autoimmune diseases by targeting the oxidized macrophage migration inhibitory factor (oxMIF), one of the most important drivers of innate and adaptive immunity and tumorigenesis. OxMIF was identified by OncoOne’s founders as the disease-related and druggable isoform of the macrophage migration inhibitory factor (MIF). The OncoOne team is focused on developing its two optimized monoclonal antibodies, ON104 and ON203, to leverage the high-value potential of oxMIF as a target for the treatment of inflammatory and autoimmune disorders as well as solid tumors, respectively. Equipped with a successful early-stage drug development track-record as well as a uniquely deep understanding of the target itself, OncoOne is advancing its lead assets toward Phase 1 clinical studies. OncoOne’s founders and management team is comprised of professionals experienced in business and science management. The leadership team has a long history in industrial drug development, antibody engineering and oncology as well as immunology research. Each member of the management team has successfully contributed to the development of clinical drug candidates, patents, and scientific publications. The company has raised EUR 18M to-date and has established a global network of research collaborations.